

Physiological and Biochemical Basis of Clinical Liver Function Tests

A Review

Lisette T. Hoekstra, MD, Wilmar de Graaf, MD, PhD, Geert A. A. Nibourg, MD, Michal Heger, PhD, Roelof J. Bennink, MD, PhD, Bruno Stieger, PhD, and Thomas M. van Gulik, MD, PhD

Objective: To review the literature on the most clinically relevant and novel liver function tests used for the assessment of hepatic function before liver surgery.

Background: Postoperative liver failure is the major cause of mortality and morbidity after partial liver resection and develops as a result of insufficient remnant liver function. Therefore, accurate preoperative assessment of the future remnant liver function is mandatory in the selection of candidates for safe partial liver resection.

Methods: A MEDLINE search was performed using the key words “liver function tests,” “functional studies in the liver,” “compromised liver,” “physiological basis,” and “mechanistic background,” with and without Boolean operators.

Results: Passive liver function tests, including biochemical parameters and clinical grading systems, are not accurate enough in predicting outcome after liver surgery. Dynamic quantitative liver function tests, such as the indocyanine green test and galactose elimination capacity, are more accurate as they measure the elimination process of a substance that is cleared and/or metabolized almost exclusively by the liver. However, these tests only measure global liver function. Nuclear imaging techniques (^{99m}Tc -galactosyl serum albumin scintigraphy and ^{99m}Tc -mebrofenin hepatobiliary scintigraphy) can measure both total and future remnant liver function and potentially identify patients at risk for postresectional liver failure.

Conclusions: Because of the complexity of liver function, one single test does not represent overall liver function. In addition to computed tomography volumetry, quantitative liver function tests should be used to determine whether a safe resection can be performed. Presently, ^{99m}Tc -mebrofenin hepatobiliary scintigraphy seems to be the most valuable quantitative liver function test, as it can measure multiple aspects of liver function in, specifically, the future remnant liver.

Keywords: compromised liver, functional studies in the liver, liver function tests, mechanistic background, physiological basis

(*Ann Surg* 2013;257: 27–36)

Liver failure is the major cause of mortality and morbidity after partial liver resection and develops as a result of insufficient functional remnant liver mass.¹ Postresectional liver function largely depends on the quantity and quality of the remnant liver, the latter being inversely proportional to underlying liver disease such as steatosis, cirrhosis, and cholestasis. Assessment of liver function is, therefore, crucial in the preoperative workup of patients who require (extensive) liver resection.

Computed tomography volumetry is currently the standard method to determine whether a patient can safely undergo liver resection. When using computed tomography volumetry, a liver resection can be safely performed when the functional remnant liver volume is larger than 25% to 30% of total liver volume in case of normal liver parenchyma.^{2,3} In patients with underlying liver disease, a margin of 40% is taken into account.⁴ However, liver volume does not necessarily reflect liver function, especially in patients with a compromised liver.^{5,6} Therefore, it is important to reliably assess hepatic function before liver surgery in addition to computed tomography volumetry.

Several liver function tests, including passive liver function tests (biochemical parameters and clinical grading systems), dynamic quantitative liver function tests (time-based uptake or metabolic capacity of infused compounds), molecular nuclear imaging techniques, and bioenergetic tests, have been developed in the last decade. This review primarily focuses on dynamic tests for the measurement of hepatic function before liver surgery. In addition, the application of quantitative liver function tests is discussed from the perspective of preoperative risk assessment in patients with diseased liver parenchyma.

DEFINITION OF LIVER FUNCTION AND CLINICAL IMPLICATIONS

The liver is responsible for a spectrum of functions including the uptake, metabolism, conjugation, and excretion of various endogenous and foreign substances, in which transporters play an important role (Fig. 1). The liver also provides an immunological function, as the reticuloendothelial capacity of the liver plays a role in phagocytosis, and clearance of microorganisms and endotoxins from the portal blood.⁷ The secretion of bile is an important end point of liver function, and the production of bile immediately ceases when perfusion of the liver is arrested. The complexity of liver function is best reflected by our inability to restore full liver function during liver failure, insofar as liver assist devices and bioartificial livers have not yet proven to fully substitute all the components of liver function.^{8,9} In addition, there is no liver function test available that measures all components of liver function.

Whereas the definition of liver function is comprehensive, a unanimous definition of posthepatectomy liver failure is lacking in the literature.¹⁰ This makes comparison between study outcomes difficult. Recently, a definition of posthepatectomy liver failure has been proposed that allows objective comparisons in future studies.¹⁰ Nevertheless, liver surgery starts and ends with restricted information on the functionality of the organ with insufficient objective means to gauge whether the liver is failing postoperatively. In addition, liver failure depends on whether the preoperative remnant liver function has been preserved during the surgical procedure. There are many variations in surgical techniques and possibilities of technical errors that may lead to deterioration of remnant liver function. Consequently, none of the available tests is completely accurate in predicting postoperative function of the remnant liver.¹¹

From the Academic Medical Center, Amsterdam, The Netherlands.

Disclosure: The authors declare no conflicts of interest.

Reprints: Lisette Temke Hoekstra, MD, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. E-mail: l.t.hoekstra@amc.uva.nl.

Copyright © 2012 by Lippincott Williams & Wilkins

ISSN: 0003-4932/12/25701-0027

DOI: 10.1097/SLA.0b013e31825d5d47




FIGURE 1. Schematic overview of 2 prominent features of liver function, basolateral and canalicular transport of compounds and protein synthesis, that are pertinent to this review. The anatomical features are identified and the arrows indicate the direction of transport. Hepatic transporters located at the basolateral side of hepatocytes (white structures) are responsible for the transport of compounds from the circulation into the cell [(sodium-taurocholate co-transporting polypeptide and the organic cation transporter family, comprising the organic cation transporter 1, organic cation transporter 2, and organic cation transporter 3 isoforms], out of the cell [2 isoforms of the ATP-binding cassette family: multidrug resistance-associated protein, or bidirectionally the organic anion transporting polypeptide family, comprising the organic anion transporting polypeptide 1A2, organic anion transporting polypeptide 1B1, and organic anion transporting polypeptide 1B3 isoforms, and the organic transporter family, comprising the organic transporter 2 and organic transporter 3 isoforms]. The asialoglycoprotein receptor removes asialoglycoproteins from the circulation. Intracellularly transported compounds may undergo biotransformation (eg, glucuronidation) or be metabolized (these liver function aspects are not shown), after which they may be transported back into the circulation or excreted into bile. All canalicular transporters (grey structures) are unidirectional and include several members of the ATP-binding cassette family [multidrug resistance protein 2, ATP-binding cassette subfamily B member 1, also called multidrug resistance1], MDR3 P-glycoprotein, and ATP-binding cassette subfamily G members 2, 5, and 8), the bile salt export pump, and probable phospholipid-transporting ATPase IC. The protein synthesis function is indicated by the deoxyribonucleic acid helix → protein crystal structure.

PASSIVE LIVER FUNCTION TESTS

Bilirubin

Plasma bilirubin concentration provides indirect information on the uptake, conjugation, and excretion function of the liver. Elevated plasma concentrations of bilirubin are specific markers for serious liver injury and, therefore, liver function loss. After formation of unconjugated (“indirect”) bilirubin, it is bound to albumin for transport to the liver. Bilirubin is taken up by hepatocytes, where it is bound by a group of cytosolic proteins, mainly glutathione S-transferases, to prevent efflux from the cell.¹² Bilirubin is conjugated to glucuronic acid (“direct bilirubin”) under the catalytic activity of UDP-glucuronosyltransferase 1-1, which converts conjugated bilirubin from a highly hydrophobic molecule to a relatively hydrophilic molecule.¹² Conjugated bilirubin is then excreted into

the bile across the canalicular membrane as bilirubin diglucuronide by the conjugate export pump multidrug resistance protein 2.^{13,14}

The specific organic anion transporting polypeptide transporter for bilirubin remains controversial.¹⁵ Bilirubin is transported into the cell more effectively by organic anion transporting polypeptide 1B1 than by organic anion transporting polypeptide 1B3, which was demonstrated in uptake studies using organic anion transporting polypeptide 1B1- or organic anion transporting polypeptide 1B3-transfected *Xenopus laevis* oocytes.¹⁶ Contrastingly, Cui et al¹⁴ reported that the transport of bilirubin into human embryonic kidney cells is facilitated by organic anion transporting polypeptide 1B1 but not by organic anion transporting polypeptide 1B3,¹⁵ whereas Wang et al¹⁷ showed that a role for organic anion transporting polypeptide 1B1 in bilirubin transport is unlikely. However, recent pharmacogenetic studies have linked polymorphisms in the *SLCO1B1* and *SLCO1B3* genes, which encode the organic anion transporting polypeptide 1B1 and 1B3 isoforms, to elevated serum levels of unconjugated and conjugated bilirubin.^{18–20} Similarly, mice lacking the *Sclot1* and *Sclotb* genes exhibit a more than 40-fold increase in total serum bilirubin levels (predominantly conjugated bilirubin) and a 2.5-fold increase in unconjugated bilirubin, whereas conjugated bilirubin in serum is undetectable in the parent strain.²¹ Moreover, inactivation or disruption of *Sclotb2* in mice leads to mild hyperbilirubinemia.^{22,23}

Given the relevance of the organic anion transporting polypeptide 1B1 and 1B3 isoforms in the uptake of unconjugated and conjugated bilirubin, any liver pathology that affects organic anion transporting polypeptide expression automatically alters bilirubin kinetics. For example, cytokines released by Kupffer cells during liver inflammation (eg, during cholestasis, steatosis/steatohepatitis), and ischemia/reperfusion²⁴ can influence the expression of different organic anion transporting polypeptide isoforms independently^{25,26} and hence, skew bilirubin-related test outcomes.

In addition, bilirubin levels may also be influenced by nonhepatic factors such as an increased production as results of hemolysis during sepsis.²⁷ Hemoglobin and lactic acid dehydrogenase are released during hemolysis, which result in an increase in indirect bilirubin and urobilinogen, a product of bilirubin reduction that becomes elevated in certain liver diseases such as hepatitis. Therefore, plasma bilirubin concentration is not a parameter of liver function per se in these instances. The plasma bilirubin concentration is often used in combination with other laboratory markers of hepatopathology (eg, liver aminotransaminase levels, albumin levels) and/or clinical grading systems such as the Child-Pugh (see the Child-Pugh Score section) and MELD (model for end-stage liver disease) scores.

Albumin and Coagulation Factor Synthesis

Albumin and proteins involved in secondary hemostasis and fibrinolysis, including vitamin K-dependent coagulation proteins (factors II, VII, IX, X, protein C, protein S, and protein Z) and factor V, XIII, fibrinogen, antithrombin, α 2-plasmin inhibitor, and plasminogen, are exclusively synthesized by the liver, and their plasma concentrations are, therefore, used as indirect indicators of liver synthesis function. Albumin, clotting factors, and coagulation parameters such as the international normalized ratio are measured by routine clinical chemistry. In liver disease, there is a decrease in the synthesis of albumin and coagulation factors, resulting in an increase in prothrombin time and international normalized ratio.

CLINICAL GRADING SYSTEMS

Clinical grading systems such as the Child-Pugh and MELD scores combine several biochemical parameters with clinical symptoms of insufficient liver function. For liver resections, the Child-Pugh score is deemed more relevant inasmuch as the MELD score is very narrow in patients undergoing liver resection.

Child-Pugh Score

The Child-Pugh score, a widely used clinical scoring system, includes total plasma bilirubin level, plasma albumin level, and prothrombin time together with the presence or absence of encephalopathy and ascites. The Child-Pugh scoring system is particularly useful in selecting patients with hepatocellular carcinoma (HCC) and cirrhosis for resection or transplantation. In Western clinical practice, most class Child B and C patients are candidates for transplantation, leaving class Child A patients eligible for resection. In these Child A patients, the Child-Pugh score has been shown to be quite variable and may be unreliable for predicting the outcome of liver resections.^{28–30}

DYNAMIC QUANTITATIVE LIVER FUNCTION TESTS

Dynamic quantitative liver function tests measure the elimination of a substance in time. Because the substances used for these tests are cleared and/or metabolized almost exclusively by the liver, the dynamic quantitative liver function tests constitute a more accurate measure of the specific aspects of liver function.

Indocyanine Green Clearance Test

The indocyanine green clearance test was initially devised for the measurement of blood flow and later employed for the assessment of liver function by measuring functional hepatocyte mass. It is now the most widely used quantitative liver function test in the clinical setting.³¹ Indocyanine green is a tricarbochrome dye that binds to albumin,^{32,33} α 1-lipoproteins,²⁸ and β -lipoproteins.³² It distributes uniformly in the blood within 2 to 3 minutes after intravenous injection of 25 or 50 mg of indocyanine green (dissolved in 5- or 10-mL sterile water, respectively). Indocyanine green is exclusively cleared by hepatocytes via organic anion transporting polypeptide 1B3 and sodium-taurocholate cotransporting polypeptide¹⁵ and excreted into the bile without biotransformation^{32,34,35} by the ATP-dependent export pump multidrug-resistance-associated protein 2.³⁶ Under normal conditions, indocyanine green has a high hepatic extraction rate and its uptake is rate limited by blood flow.^{15,33} In addition, the clearance of indocyanine green from the blood is similar to that of various endogenous and exogenous substances such as bilirubin, hormones, drugs, and toxins. The indocyanine green clearance test, therefore, reflects several important functional parameters of the liver, including blood flow–dependent clearance and transporter capacity.¹⁵

Elimination of indocyanine green from the blood is dependent on hepatic blood flow, cellular uptake, and biliary excretion.^{35,37} After administration, the blood level falls exponentially for about 20 minutes, by which time approximately 97% of the dye is excreted into the bile.³⁴ The indocyanine green clearance rate is determined by serum sampling or pulse dye densitometry, using an optical sensor placed on the finger.^{38–40} The results of indocyanine green tests can be expressed in several ways, including the plasma disappearance rate (ICG-PDR), the indocyanine green elimination rate constant (indocyanine green- k), and the indocyanine green-R15, which describes the percentage of clearance of indocyanine green at 15 minutes or, conversely, circulatory retention of indocyanine green during the first 15 minutes after bolus injection.⁴¹ Indocyanine green-PDR is the most commonly used parameter, with normal ranges between 16% and 25% per minute.^{32,37,42}

The indocyanine green clearance test has been widely used in critically ill patients and in patients with chronically reduced hepatic function.^{32,37} For example, it has been reported that the indocyanine green-R15 value is a better indicator of liver function than the Child-Pugh classification in patients who had undergone cardiac surgery. In these patients, a high indocyanine green retention rate at 15 minutes correlated with a high rate of mortality.⁴³ Furthermore, the indocyanine green clearance test was found to be a better discrim-

inating preoperative test for evaluating hepatic functional reserve in patients with HCC than the aminopyrine breath test and the amino acid clearance test.⁴⁴ Monitoring of indocyanine green elimination is also indicated for the evaluation of liver function in organ donors and recipients in the liver transplantation setting. Several cutoff values for a safe resection have been described in the literature. The indocyanine green-PDR is an important prognostic factor for postoperative recovery and survival and has to be higher than 5% per minute.⁴⁵ Another study reported a safety limit of 14% for indocyanine green-R15 for a major hepatectomy.⁴⁴

However, under certain conditions, indocyanine green clearance test results may be misrepresentative of the underlying liver disease, as confirmed by several studies that found no significant correlations between indocyanine green-15 clearance rates and liver histology as well as clinical outcome.^{46,47} Mortality has been noted in patients with normal indocyanine green-15 values, and survival has been observed in patients with predicted poor outcome on the basis of preoperative indocyanine green-15 values.^{46,48,49} Moreover, factors such as hepatic hemodynamics may influence test outcomes. Variations in hepatic blood flow caused by intrahepatic shunting or thrombosis will influence indocyanine green clearance rate, rendering the test less predictive.⁴⁷ Under pathophysiological circumstances, the transport capacity may be reduced either because of the down-regulation of organic anion transporting polypeptide transporters⁵⁰ or by competitive inhibition due to excessively present bilirubin.¹⁴ With respect to the former, cytokines such as tumor necrosis factor α and interleukin 6, which are released by Kupffer cells in patients with steatosis and hepatitis can affect the expression of organic anion transporting polypeptide isoforms and sodium-taurocholate cotransporting polypeptide, thereby affecting indocyanine green uptake by the liver.¹⁵ Consequently, the indocyanine green test may be of limited value during liver diseases in which the parenchyma is compromised and is improper for cholestatic patients. Another aspect of the indocyanine green clearance test is that it reflects global liver function but does not take into account regional variations that may occur in the liver, particularly under pathological conditions, thereby obscuring a possible functional disadvantage of the segments to be preserved. However, this applies to every clearance test that is performed without an imaging component.

Galactose Elimination Capacity Test

The galactose elimination capacity test determines the metabolic capacity of the liver. Galactose is phosphorylated intracellularly to galactose-1-phosphate by galactokinase. Galactose-1-phosphate is then converted to glucose-1-phosphate by the action of 4 enzymes in the Leloir pathway.^{51,52} Galactose is administered intravenously, and the galactose elimination capacity is calculated from serial serum samples from 20 to 50 minutes postinjection, making the test somewhat time consuming. The galactose elimination capacity has shown prognostic significance in chronic liver disease,^{53,54} such as fulminant hepatic failure,⁵⁵ primary biliary cirrhosis,^{56–58} and chronic active hepatitis.^{54,57,59} Abnormal clearance has also been frequently observed in patients with metastatic liver neoplasms.⁵⁷ A low galactose elimination capacity value can predict postoperative complications and death, whereas a high galactose elimination capacity value is associated with longer survival.⁵⁴ As is the case with most liver function tests, alterations in environmental conditions or liver metabolism will affect test outcomes. Galactose is an essential component of membrane glycoproteins and glycolipids. During liver regeneration, an increased membrane synthesis can lead to an augmented galactose demand.²⁴ Furthermore, galactose can be converted into glucose, which is used as an energy source during anaerobic respiration, especially during fasting.²⁴ As a result, altered galactose kinetics during liver regeneration and fasting^{24,60} may provide

false-positive results with respect to liver function. In addition, galactose elimination capacity measures only total liver function.

MOLECULAR NUCLEAR IMAGING TECHNIQUES

^{99m}Tc-Galactosyl Serum Albumin Scintigraphy

^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin is an analogue ligand of asialoglycoprotein that binds to asialoglycoprotein receptors on the hepatocyte cell membrane.^{61,62} The asialoglycoprotein receptors consist of 2 subunits, hepatic lectins 1 and 2, and is expressed only on the hepatocyte sinusoidal surface facing the space of Disse.^{61–66} Asialoglycoproteins are taken up by the asialoglycoprotein receptors via receptor-mediated endocytosis. The liver is the only uptake site for ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin and is therefore an ideal agent for receptor-targeted functional liver scintigraphy. A significant decrease in asialoglycoprotein receptor expression has been observed in patients with chronic liver problems,³⁰ coinciding with the accumulation of asialoglycoproteins in the circulation.^{67,68}

Planar ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy has proven valuable for the assessment of liver function in cirrhotic patients and demonstrated a good relationship with conventional liver function tests such as antithrombin, total and direct bilirubin, prothrombin time, indocyanine green clearance,⁶⁹ Child-Pugh classification, and histology (hepatic activity index score).^{47,70} A discrepancy between the indocyanine green clearance test and ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy has been described in 9% to 20% of the patients in whom the histological severity of disease was better reflected by ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy.^{71,72} Because bilirubin does not bind to asialoglycoprotein receptors, ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy is not influenced by hyperbilirubinemia.⁷³ Also, as there is practically no biliary excretion of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin, the radiocompound is perfectly suited for single photon emission computed tomography. On the contrary, the test is not suitable for the evaluation of biliary obstruction as a possible cause of secondary hepatocellular failure, as can be seen in patients with cholangiocarcinoma.

In dynamic ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy, images are obtained after an intravenous bolus of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin, using a gamma camera positioned over the heart and liver region. The blood clearance and hepatic uptake are obtained by probing regions of interest in the heart and the liver, respectively, for the accumulation of radiolabel in time. For the actual kinetics of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin receptor binding, several complex kinetic models have been developed. Although many different parameters can be calculated from different kinetic models, these are often too complex and, therefore, not widely used in the context of liver surgery.⁷⁴ The hepatic uptake ratio of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin (LHL15) and the blood clearance ratio (HH15) are the most commonly used parameters in planar dynamic ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy (Fig. 2). The HH15 is calculated by dividing the radioactivity of the heart regions of interest at 15 minutes after ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin injection by the radioactivity of the heart regions of interest at 3 minutes after injection. LHL15 is calculated by dividing the radioactivity of the liver regions of interest by the radioactivity of the liver plus heart regions of interests at 15 minutes after injection.^{71,75,76} The modified receptor index,

which represents a quantitative measurement of hepatic function, can subsequently be determined by dividing the LHL15 by the HH15, calculated from the radioactivity of the liver and the heart.⁷¹

Multiple studies have addressed the use of preoperative planar dynamic ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy for predicting postoperative complications.^{61,72,77,78} The preoperative hepatic uptake ratio of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin (LHL15) proved a reliable indicator for predicting postoperative complications in patients with HCC and chronic liver disease, showing significantly lower values in patients with major postoperative complications.^{47,78} Specific cutoff values for LHL15 (0.900 and 0.875)^{72,77,78} have been used to select patients with a high risk for complications. However, these cutoff values were mostly not based on robust risk analysis but were rather set arbitrarily. Postoperative liver failure was also observed in patients with a relatively normal liver function (LHL15 >0.875). This can be explained by the fact that LHL15 measures only preoperative total liver function and not the function of the functional remnant liver per se.

^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy can be combined with computed tomography to add anatomical detail to the liver function test. Static ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography has the ability to measure segmental liver function and functional liver volume.^{79,80} The outline extraction method is a simple technique to calculate the functional liver volume, using a specific cutoff value to automatically outline the liver.⁷⁹ Typically, a cutoff value of 35% to 39% is used for delineating the liver.^{79,81} Although static single photon emission computed tomography has the ability to visualize regional differences in liver function, functional liver volume measured by the outline extraction method does not take into account the regional functional differences within the delineated liver volume.⁷⁴ As an alternative to static single photon emission computed tomography, dynamic single photon emission computed tomography has been used to measure the uptake dynamics of ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin in a 3-dimensional manner using a rapidly rotating multidetector gamma camera.

^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography provides the opportunity to specifically assess the functional remnant liver.^{80,82} Preoperative functional volume measured by static ^{99m}Tc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography has proven more suitable for predicting remnant liver function than computed tomography volumetry in a study group with predominantly cirrhotic patients.^{79,80} In cirrhotic patients, advanced fibrosis is accompanied by a reduction in functional hepatocyte mass,⁸² whereas computed tomography volumetry cannot distinguish between functional and non-functional liver tissue. In addition, tumor-induced compression of surrounding liver tissue, bile ducts,⁷⁹ and/or blood vessels⁸³ can impact regional liver function, whereas liver volume is sustained over a longer time period. However, the aforementioned outline extraction method for static single photon emission computed tomography images is based on the assumption that liver function is uniformly distributed in the tissue included within the cutoff value. Especially in tumor-bearing, but also compromised, livers, function can be distributed heterogeneously.^{5,74,84} Therefore, total functional liver




FIGURE 2. Planar ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy. The hepatic uptake ratio (LHL15) and blood disappearance ratio (HH15) is calculated from the ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin time-activity curves from the heart (gray) and the liver (black) (left panel). The HH15 is calculated by dividing the radioactivity of the heart regions of interest at 15 minutes after ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin injection by that at 3 minutes after injection. LHL15 is calculated by dividing the radioactivity of the liver regions of interest by the radioactivity of the liver plus heart regions of interest at 15 minutes after injection.⁷⁵ The subscript values designate time, the capitalized letters indicate the organ according to the legend. The blood disappearance constant (K_L) is calculated from the liver uptake curve using the disappearance half-time ($T_{1/2}$) (right panel). Adapted with permission from de Graaf et al.⁷⁴

volume as measured by static ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography does not necessarily correlate with the intrinsic liver function. This potential shortcoming may be circumvented by using dynamic planar ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography^{76,82} in a 3-dimensional manner (ie, by using a rapidly rotating multidetector gamma camera^{74,76,82}) with which the intrinsic remnant liver function can be measured. In addition, dynamic planar ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin single photon emission computed tomography can be used to predict postoperative complications with a high level of accuracy.^{82,85}

^{99m}Tc -Mebrofenin Hepatobiliary Scintigraphy

^{99m}Tc -mebrofenin [^{99m}Tc -N-(3-bromo-2,4,6-trimethoxyacetanilide)iminodiacetic acid] is an iminodiacetic acid analogue that circulates in an albumin-bound form.^{44,86,87} Dissociation of mebrofenin from albumin occurs in the space of Disse, after which mebrofenin is taken up by hepatocytes via human organic anion transporting polypeptide 1B1 and organic anion transporting polypeptide 1B3.¹⁵ Similar to indocyanine green, ^{99m}Tc -mebrofenin undergoes biliary excretion without undergoing biotransformation and is therefore an ideal tracer for the biliary tract.^{15,88} The canalicular transporter includes multidrug resistance protein-2.⁸⁹ Although ^{99m}Tc -mebrofenin is not metabolized, the transport mechanism resembles transport of various endogenous and exogenous substances such as bilirubin, hormones, drugs, and toxins.⁹⁰ ^{99m}Tc -mebrofenin hepatobiliary scintigraphy, therefore, measures a physiologically representative function of the liver.

^{99m}Tc -labeled iminodiacetic acid analogues were first used for the diagnosis of multiple biliary diseases.^{86,90,91} More recently, the application of ^{99m}Tc -labeled iminodiacetic acid agents have been pro-

posed for the assessment of liver function.⁹² Measurement of hepatic uptake function by the clearance rate of the iminodiacetic acid analogue Iodida was first described by Ekman et al.⁹³ The hepatic uptake of mebrofenin is calculated in a similar manner to that of Iodida. Because of the rapid biliary excretion of mebrofenin, ^{99m}Tc -mebrofenin hepatobiliary scintigraphy is primarily used for dynamic rather than static assessment of liver function. After intravenous injection of ^{99m}Tc -mebrofenin, dynamic hepatobiliary scintigraphy is performed with a gamma camera,⁷⁴ as addressed in the previous section on ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy. To determine global liver function, the hepatic uptake of ^{99m}Tc -mebrofenin is determined by assigning a region of interest around the liver, the heart (serving as blood pool), and the total field of view, as is illustrated in Figure 3 (top row).

Three different time-activity curves are generated on the basis of these regions of interests with which the uptake rate (%/min) can be calculated. Radioactivity values acquired between 150 and 350 seconds postinjection are used to ensure that the calculations are made during a phase of homogenous distribution of the agent in the blood pool before biliary excretion takes place.^{94,95} Remnant liver function can then be calculated by dividing the summed counts (150–350 s postinjection) within the delineated functional remnant liver by the total liver counts within the same time frame and multiplying this factor with total liver ^{99m}Tc -mebrofenin uptake rate. Finally, total liver ^{99m}Tc -mebrofenin uptake rate (%/min/ m^2) can be calculated by dividing the time-activity curve(s) by the patient's body surface area which, therefore, individualizes the assessment according to patient characteristics.^{94,95}

A clinical study compared the indocyanine green clearance test with ^{99m}Tc -mebrofenin hepatobiliary scintigraphy in patients undergoing liver resection and showed a good correlation between the 2 tests.⁹⁵ In a subsequent study, hepatobiliary scintigraphy was validated as a tool to measure total liver function and functional remnant




FIGURE 3. ^{99m}Tc -mebrofenin hepatobiliary scintigraphy (top row) and ^{99m}Tc -mebrofenin single photon emission computed tomography (bottom row). The upper left panel shows superimposed images of dynamic planar hepatobiliary scintigraphy scans from 150 to 350 seconds after intravenous injection of ^{99m}Tc -mebrofenin, which ensures that hepatic uptake calculations are performed during a phase of homogenous distribution of ^{99m}Tc -mebrofenin. A region of interest is drawn around the entire liver (black line), the mediastinum (blood pool, white line), the total field of view (not shown), and the future remnant liver (grey line). The respective, color-coded time–activity curves are depicted in the upper right panel. The time–activity curves of the liver (segments) are typically corrected for background, that is, the blood pool time–activity curve, by subtraction. The uptake of ^{99m}Tc -mebrofenin (D) by the liver is calculated as an increase in blood pool–corrected ^{99m}Tc -mebrofenin uptake (y) over a predefined time interval (x), usually 200 seconds. The bottom left and right panels depict an example of ^{99m}Tc -mebrofenin single photon emission computed tomography with a matching computed tomography scan. An inhomogeneous distribution of ^{99m}Tc -mebrofenin is seen in liver segments 7 and 8 (arrows) due to regional cholestasis in a patient with hilar cholangiocarcinoma. The matching computed tomography scan shows dilated bile ducts (arrowheads) in the same liver segments.

liver before liver surgery.⁹⁴ The latter was validated by comparing preoperative functional remnant liver with actual postoperative remnant liver function immediately after surgery. A strong positive correlation ($r = 0.95$) was found between functional remnant liver determined preoperatively and the actually measured value 24 hours after resection. Also, 3 months after the resection, there was a strong positive correlation ($r = 0.81$) between liver function assessed by ^{99m}Tc -mebrofenin hepatobiliary scintigraphy and the indocyanine green clearance test. A slightly weaker relationship ($r = 0.61$) was found between functional liver regeneration and liver volume increase after 3 months, which may account for some of the discrepancies between volumetric regeneration of the remnant liver and clinical (ie, functional) outcome after liver resection.⁹⁴

Two clinical studies further validated the utility of ^{99m}Tc -mebrofenin hepatobiliary scintigraphy in the preoperative prediction of postoperative liver failure. A study by Dinant et al⁸⁷ encompassed 46 patients with and without parenchymal disease. Preoperative measurement of functional remnant liver by planar dynamic ^{99m}Tc -mebrofenin hepatobiliary scintigraphy proved more valuable

than measurement of functional remnant liver volume by computed tomography volumetry for risk assessment of postoperative liver failure and liver failure–related mortality.⁸⁷ A safe resection could be performed in patients with afunctional remnant liver uptake above 2.5%/min/m² body surface area, with a 3% chance of developing postoperative liver failure and liver failure–related mortality. However, in patients with a functional remnant liver uptake below 2.5%/min/m² body surface area, the risk of postoperative liver failure increased to 56%. A study by de Graaf et al⁶ addressed a population of high-risk patients requiring major hepatic resections (≥ 3 liver segments), where accurate measurement of functional remnant liver is critical in the assessment of potential resectability. For this population, receiver operating characteristic curve analysis yielded an almost similar functional remnant liver cutoff of 2.7%/min/m² body surface area. We now use 2.7%/min/m² body surface area as the advised cutoff for functional remnant liver.

Owing to technical advances, new rotating gamma cameras have been developed that enable fast ^{99m}Tc -mebrofenin single photon emission computed tomography, thereby accounting for the rapid

hepatic uptake and biliary excretion kinetics of mebrofenin. Dual-head gamma cameras now enable simultaneous data acquisition in the anterior and posterior projections, from which a geometric mean activity can be calculated, thereby reducing the attenuation bias. In addition, these gamma cameras can be used in conjunction with computed tomography scanners to combine the functional data from ^{99m}Tc -mebrofenin single photon emission computed tomography with the anatomic information from the computed tomography scan, enabling 3-dimensional measurement of segmental liver function and liver functional volume (Fig. 3, bottom row). The functional remnant liver can be outlined manually on the low-dose computed tomography scan and linked to the single photon emission computed tomography images. The delineated functional remnant liver on contrast-enhanced computed tomography scans can subsequently be used as a constant reference. A recent study, in which functional remnant liver was assessed by ^{99m}Tc -mebrofenin single photon emission computed tomography with low-dose computed tomography, demonstrated that the combination of single photon emission computed tomography with the dynamic uptake data from planar hepatobiliary scintigraphy (geometric mean data) allowed complete and accurate prediction of postoperative remnant liver function,⁵ whereby the single photon emission computed tomography and computed tomography image overlays provided valuable visual information on liver function distribution.

The timing of the single photon emission computed tomography is a challenge when a dynamic tracer such as ^{99m}Tc -mebrofenin is used, which is first taken up by the liver and subsequently excreted in the bile. The single photon emission computed tomography acquisition is, therefore, centered on the peak of the hepatic time-activity curve, because the amount of radioactivity within the liver is relatively stable during this phase. In patients with fast hepatic uptake, biliary excretion is already visible during the single photon emission computed tomography phase. Accumulation of radioactivity in the small bile ducts results in voxels with relatively high counts, disturbing calculation of total and regional liver function and volume. Consequently, the activity within the extrahepatic bile ducts must be masked out and the intrahepatic bile ducts must be replaced by the average counts of the normal surrounding liver tissue. The outline extraction method can subsequently be used to automatically outline the liver and calculate total functional liver volume.

Furthermore, regions of interest can be drawn around parts of the liver to calculate regional differences in the ^{99m}Tc -mebrofenin uptake rate. Segmental liver function, such as that of the functional remnant liver, can be measured by dividing the counts within the delineated segment by the total counts within the entire liver. For calculation of the functional remnant liver, this count ratio is multiplied by total liver ^{99m}Tc -mebrofenin uptake as measured by dynamic hepatobiliary scintigraphy. The regional uptake of ^{99m}Tc -mebrofenin can be assessed with small intra- and interobserver variations.^{87,94}

Because ^{99m}Tc -mebrofenin hepatobiliary scintigraphy has the ability to selectively measure functional remnant liver, it is one of the few liver function tests that can be used to measure the increase in functional remnant liver after portal vein embolization. A recent study showed that functional increase of the remnant liver measured by ^{99m}Tc -mebrofenin hepatobiliary scintigraphy exceeds the volumetric increase of the functional remnant liver, suggesting that the waiting time until resection may be shorter than that indicated by volumetric data.⁹⁶

Liver uptake of iminodiacetic acid agents can be affected by high plasma levels of bilirubin because of the competitive affinity of bilirubin for the respective transporters. Of all iminodiacetic acid analogues, however, ^{99m}Tc -mebrofenin shows the highest hepatic uptake, minimal urinary excretion, and a strong resistance against displacement by a high plasma bilirubin concentration.⁹⁷ Therefore,

^{99m}Tc -mebrofenin is considered as the most suitable iminodiacetic acid analogue for hepatic and biliary diagnostic procedures. In addition, ^{99m}Tc -mebrofenin uptake can be hindered by hypoalbuminemia, as albumin is the main plasma carrier of mebrofenin. Nevertheless, hypoalbuminemia and hyperbilirubinemia can be signs of impaired liver function during liver disease and therefore a decreased uptake of ^{99m}Tc -mebrofenin in patients with hypoalbuminemia can still provide an accurate reflection of liver function under these circumstances.

DISCUSSION

Accurate measurement of liver function before liver resection is crucial in the assessment of hepatic functional reserve and resectability, especially in patients who require major resection and patients with underlying parenchymal disease. For liver surgery, computed tomography volumetry is currently the gold standard method to decide on resectability. Several quantitative liver function tests can complement computed tomography volumetry and may even replace computed tomography volumetry in the future.

In patients with liver-specific diseases, accurate assessment of liver function is critical for the selection of treatment options. Liver steatosis and steatohepatitis, for example, are associated with an increased risk of liver failure after partial liver resection, especially after neoadjuvant chemotherapy, or in living donor liver transplantation.⁹⁸ When computed tomography volumetry is used as a prognostic tool for surgical outcome, a functional overestimation can be made in patients with steatosis. The accumulation of triacylglycerols in hepatocytes leads to hepatocyte enlargement in combination with steatosis-induced perfusion defects, that is, phenomena that distort the actual liver function when deduced from computed tomography scans. Indocyanine green clearance and ^{99m}Tc -mebrofenin hepatobiliary scintigraphy, therefore, possess the potential to assess hepatic function in steatotic livers due to the combination of impaired parenchymal perfusion and liver dysfunction.⁹⁹

The same principles apply to cirrhotic livers, where fibrosis is accompanied by a reduction in functional hepatocytes that concurs with the formation of fibrous tissue septa that separate hepatocyte nodules, leading to altered resistance to hepatic blood flow and portal hypertension.^{100,101} The most commonly used liver function tests in cirrhotic patients include hyaluronic acid uptake, the Child-Pugh classification, ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy, and the indocyanine green test, albeit any liver function test is capable of detecting a reduced number of functional hepatocytes in combination with impaired hepatic blood flow. In any case, liver function tests provide more accurate information on the functional status of the liver than computed tomography volumetry.

Prolonged cholestasis produces hepatocellular injury and fibrosis. The uptake of ^{99m}Tc -mebrofenin and indocyanine green is impaired under these conditions because of the competitive uptake of bilirubin and indocyanine green/mebrofenin by the same cellular transporter systems. Although this impaired uptake is indicative of the uptake function of the liver at that specific time, it does not reflect the function of the liver after surgery once the biliary obstruction has been resolved. Preoperative assessment of liver function using the indocyanine green clearance test or ^{99m}Tc -mebrofenin hepatobiliary scintigraphy, therefore, requires complete biliary drainage of at least the functional remnant liver in patients with concomitant obstruction of (part of) the biliary tree, as seen in hilar cholangiocarcinomas.

The major disadvantage of most quantitative liver function tests such as the indocyanine green clearance test and the galactose elimination capacity is the fact that they only measure global liver function and not specifically the function of the remnant liver. Both ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy and ^{99m}Tc -mebrofenin hepatobiliary scintigraphy

have the unique ability to measure the functional remnant liver non-invasively. These tests are, therefore, also suitable for assessing the increase in remnant liver function after portal vein embolization. In addition, they allow for the simultaneous acquisition of morphological (visual) and physiological (functional) information of the liver, especially when single photon emission computed tomography-computed tomography cameras are used. It has been demonstrated in patients that the functional capacity may vary within the liver or even the functional remnant liver. With molecular imaging techniques, such regional differences in hepatic function can be detected. In addition, when radiopharmaceutical agents are used that are excreted into the bile, 2 dynamic phases can be examined, that is, hepatic uptake of the agent and secretion into the biliary system.

Both preoperative ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy and ^{99m}Tc -mebrofenin scintigraphy are validated and accurate methods for preoperative assessment of liver function and prediction of postoperative complications.^{72,87,95} Both tests are especially suitable for evaluation of liver function in patients with parenchymal liver disease. Unfortunately, the clinical implementation of ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy has been restricted, and as to date, it has not been approved in Europe and the United States but only in Japan.

In the final analysis, the most suitable liver function test for clinical use is yet to be determined. However, recent studies have provided useful insights into the proper approach toward assessing preoperative liver function. de Graaf et al²⁴ compared several quantitative liver function tests, including liver volume (computed tomography volumetry), ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy, ^{99m}Tc -mebrofenin hepatobiliary scintigraphy, the indocyanine green clearance test, and the galactose elimination capacity test, in a standardized rat model of liver regeneration. It was clearly demonstrated that volumetric assessment of the liver should in any case be complemented by liver function-specific tests. Because of the functional complexity of the liver, and because each test reflects a different component of liver function, 1 single liver function test cannot measure liver function comprehensively.^{102,103} It is, therefore, recommended to use a liver function test that (1) can be combined with imaging (eg, single photon emission computed tomography) to provide regional functional information, (2) measures a maximum number of components of liver function, and (3) is not restricted in its clinical implementation by regulatory agencies. These selection criteria automatically yield ^{99m}Tc -mebrofenin hepatobiliary scintigraphy as the most suitable liver function test, given that this test (1) can be combined with single photon emission computed tomography, (2) measures the uptake (by 2 transporters) and excretory function of the liver, and (3) does not face regulatory restrictions such as ^{99m}Tc -diethylenetriamine-pentaacetic acid-galactosyl human serum albumin scintigraphy.

REFERENCES

- van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. *Liver Int*. 2008;28:767–780.
- Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg*. 2003;7:325–330.
- Vauthey JN, Chauoi A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. *Surgery*. 2000;127:512–519.
- Clavien PA, Emond J, Vauthey JN, et al. Protection of the liver during hepatic surgery. *J Gastrointest Surg*. 2004;8:313–327.
- de Graaf W, van Lienden KP, van Gulik TM, et al. (^{99m}Tc)-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. *J Nucl Med*. 2010;51:229–236.
- de Graaf W, van Lienden KP, Dinant S, et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. *J Gastrointest Surg*. 2010;14:369–378.
- Schindl MJ, Millar AM, Redhead DN, et al. The adaptive response of the reticuloendothelial system to major liver resection in humans. *Ann Surg*. 2006;243:507–514.
- Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. *Ann Surg*. 2004;239:660–667.
- van de Kerkhove MP, Hoekstra R, Chamuleau RA, et al. Clinical application of bioartificial liver support systems. *Ann Surg*. 2004;240:216–230.
- Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery*. 2011;149:713–724.
- Fan ST. Liver functional reserve estimation: state of the art and relevance for local treatments: the Eastern perspective. *J Hepatobiliary Pancreat Sci*. 2010;17:380–384.
- Chand N, Sanyal AJ. Sepsis-induced cholestasis. *Hepatology*. 2007;45:230–241.
- Field KM, Dow C, Michael M. Part I: liver function in oncology: biochemistry and beyond. *Lancet Oncol*. 2008;9:1092–1101.
- Cui Y, König J, Leier I, et al. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. *J Biol Chem*. 2001;276:9626–9630.
- de Graaf W, Hausler S, Heger M, et al. Transporters involved in the hepatic uptake of (^{99m}Tc)-mebrofenin and indocyanine green. *J Hepatol*. 2011;54:738–745.
- Briz O, Serrano MA, Maclás RI, et al. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. *Biochem J*. 2003;371:897–905.
- Wang P, Kim RB, Chowdhury JR, et al. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. *J Biol Chem*. 2003;278:20695–20699.
- Johnson AD, Kavousi M, Smith AV, et al. Genome-wide association meta-analysis for total serum bilirubin levels. *Hum Mol Genet*. 2009;18:2700–2710.
- Sanna S, Busonero F, Maschio A, et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. *Hum Mol Genet*. 2009;18:2711–2718.
- Zhang W, He YJ, Gan Z, et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. *Clin Exp Pharmacol Physiol*. 2007;34:1240–1244.
- van de Steeg E, Wagenaar E, van der Kruijsen CM, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. *J Clin Invest*. 2010;120:2942–2952.
- Csanaky IL, Lu H, Zhang Y, et al. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. *Hepatology*. 2011;53:272–281.
- Zaher H, Meyer zu Schwabedissen HE, Tirona RG, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. *Mol Pharmacol*. 2008;74:320–329.
- de Graaf W, Bennis RJ, Heger M, et al. Quantitative assessment of hepatic function during liver regeneration in a standardized rat model. *J Nucl Med*. 2011;52:294–302.
- Krishnamurthy GT, Krishnamurthy S. Cholescintigraphic measurement of liver function: how is it different from other methods? *Eur J Nucl Med Mol Imaging*. 2006;33:1103–1106.
- Tanaka Y, Chen C, Maher JM, et al. Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. *Transplantation*. 2006;82:258–266.
- Lau WY. *Hepatocellular Carcinoma*. Singapore: World Scientific Publishing Company; 2008.
- Schneider PD. Preoperative assessment of liver function. *Surg Clin North Am*. 2004;84:355–373.
- Nagashima I, Takada T, Okinaga K, et al. A scoring system for the assessment of the risk of mortality after partial hepatectomy in patients with chronic liver dysfunction. *J Hepatobiliary Pancreat Surg*. 2005;12:44–48.
- Garcea G, Ong SL, Maddern GJ. Predicting liver failure following major hepatectomy. *Dig Liver Dis*. 2009;41:798–806.
- Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. *N Engl J Med*. 2007;356:1545–1559.

32. Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. *Transplant Proc.* 2006;38:801–802.
33. Wissler EH. Identifying a long standing error in single-bolus determination of the hepatic extraction ratio for indocyanine green. *Eur J Appl Physiol.* 2011;111:641–646.
34. Paumgartner G. The handling of indocyanine green by the liver. *Schweiz Med Wochenschr.* 1975;105:1–30.
35. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. *Chest.* 2002;122:1715–1720.
36. Sathirakul M, Suzuki H, Yasuda K, et al. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. *J Pharmacol Exp Ther.* 1993;265:1301–1312.
37. Sakka SG. Assessing liver function. *Curr Opin Crit Care.* 2007;13:207–214.
38. Okochi O, Kaneko T, Sugimoto H, et al. ICG pulse spectrophotometry for perioperative liver function in hepatectomy. *J Surg Res.* 2002;103:109–113.
39. Akita H, Sasaki Y, Yamada T, et al. Real-time intraoperative assessment of residual liver functional reserve using pulse dye densitometry. *World J Surg.* 2008;32:2668–2674.
40. Burra P, Masier A. Dynamic tests to study liver function. *Eur Rev Med Pharmacol Sci.* 2004;8:19–21.
41. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. *J Hepatobiliary Pancreat Surg.* 2005;12:16–22.
42. Kortgen A, Paxian M, Werth M, et al. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. *Shock.* 2009;32:358–365.
43. Watanabe Y, Kumon K. Assessment by pulse dye-densitometry indocyanine green (ICG) clearance test of hepatic function of patients before cardiac surgery: its value as a predictor of serious postoperative liver dysfunction. *J Cardiothorac Vasc Anesth.* 1999;13:299–303.
44. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. *Br J Surg.* 1997;84:1255–1259.
45. Inderbitzin D, Muggli B, Ringger A, et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. *J Gastrointest Surg.* 2005;9:1155–1161.
46. Lam CM, Fan ST, Lo CM, et al. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. *Br J Surg.* 1999;86:1012–1017.
47. Kwon AH, Ha-Kawa SK, Uetsuji S, et al. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (^{99m}Tc-GSA) liver scintigraphy. *Hepatology.* 1997;25:426–429.
48. Fan ST, Lai EC, Lo CM, et al. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. *Arch Surg.* 1995;130:198–203.
49. Sawada T, Kita J, Nagata H, et al. Hepatectomy for metastatic liver tumor in patients with liver dysfunction. *Hepatogastroenterology.* 2007;54:2306–2309.
50. Geier A, Wagner M, Dietrich CG, et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. *Biochim Biophys Acta.* 2007;1773:283–308.
51. Goresky CA, Bach GG, Nadeau BE. On the uptake of materials by the intact liver. The transport and net removal of galactose. *J Clin Invest.* 1973;52:991–1009.
52. Holden HM, Rayment I, Thoden JB. Structure and function of enzymes of the Leloir pathway for galactose metabolism. *J Biol Chem.* 2003;278:43885–43888.
53. Herold C, Heinz R, Niedobitek G, et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. *Liver.* 2001;21:260–265.
54. Redaelli CA, Dufour JF, Wagner M, et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. *Ann Surg.* 2002;235:77–85.
55. Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. *Gut.* 1976;17:959–964.
56. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. *Hepatology.* 1991;14:504–510.
57. Tengstrom B. The discriminatory ability of a galactose tolerance test and some other tests in the diagnosis of cirrhosis of the liver, hepatitis and biliary obstruction. *Scand J Clin Lab Invest.* 1969;23:159–168.
58. Jepsen P, Vilstrup H, Ott P, et al. The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study. *BMC Gastroenterol.* 2009;9:50.
59. Aebli N, Reichen J. The prognostic value of the serial determination of galactose elimination capacity in chronic active hepatitis [in German]. *Schweiz Med Wochenschr.* 1991;121:970–976.
60. Jansen PL, Chamuleau RA, van Leeuwen DJ, et al. Liver regeneration and restoration of liver function after partial hepatectomy in patients with liver tumors. *Scand J Gastroenterol.* 1990;25:112–118.
61. Kokudo N, Vera DR, Tada K, et al. Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. *World J Surg.* 2002;26:1342–1347.
62. Kudo M, Todo A, Ikekubo K, et al. Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. *Hepatology.* 1993;17:814–819.
63. Akaki S, Mitsumori A, Kanazawa S, et al. Technetium-99m-DTPA-galactosyl human serum albumin liver scintigraphy evaluation of regional CT/MRI attenuation/signal intensity differences. *J Nucl Med.* 1998;39:529–532.
64. Ashwell G, Steer CJ. Hepatic recognition and catabolism of serum glycoproteins. *JAMA.* 1981;246:2358–2364.
65. Hubbard AL, Wilson G, Ashwell G, et al. An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver, part I: distribution of ¹²⁵I-ligands among the liver cell types. *J Cell Biol.* 1979;83:47–64.
66. Stockert RJ, Morell AG. Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. *Hepatology.* 1983;3:750–757.
67. Sawamura T, Kawasato S, Shiozaki Y, et al. Decrease of a hepatic binding protein specific for asialoglycoproteins with accumulation of serum asialoglycoproteins in galactosamine-treated rats. *Gastroenterology.* 1981;81:527–533.
68. Suzuki Y, Kohno Y, Takeda Y, et al. Evaluation of liver function parameters by Tc-99m-GSA using multivariate analysis: a study of 47 clinical cases. *Acta Med Okayama.* 1999;53:225–232.
69. Kawamura H, Kamiyama T, Nakagawa T, et al. Preoperative evaluation of hepatic functional reserve by converted ICGR15 calculated from Tc-GSA scintigraphy. *J Gastroenterol Hepatol.* 2008;23:1235–1241.
70. Sasaki N, Shiomi S, Iwata Y, et al. Clinical usefulness of scintigraphy with ^{99m}Tc-galactosyl-human serum albumin for prognosis of cirrhosis of the liver. *J Nucl Med.* 1999;40:1652–1656.
71. Kwon AH, Ha-Kawa SK, Uetsuji S, et al. Use of technetium 99m diethylenetriamine-pentaacetic acid-galactosyl-human serum albumin liver scintigraphy in the evaluation of preoperative and postoperative hepatic functional reserve for hepatectomy. *Surgery.* 1995;117:429–434.
72. Nanashima A, Yamaguchi H, Shibasaki S, et al. Relationship between indocyanine green test and technetium-99m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: clinical evaluation and patient outcome. *Hepatol Res.* 2004;28:184–190.
73. Mimura T, Hamazaki K, Sakai H, et al. Evaluation of hepatic functional reserve in rats with obstructive jaundice by asialoglycoprotein receptor. *Hepatogastroenterology.* 2001;48:777–782.
74. de Graaf W, Bennink RJ, Vetelainen R, et al. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. *J Nucl Med.* 2010;51:742–752.
75. Kokudo N, Vera DR, Makuuchi M. Clinical application of TcGSA. *Nucl Med Biol.* 2003;30:845–849.
76. Tanaka A, Shinohara H, Hatano E, et al. Perioperative changes in hepatic function as assessed by asialoglycoprotein receptor indices by technetium 99m galactosyl human serum albumin. *Hepatogastroenterology.* 1999;46:369–375.
77. Kim YK, Nakano H, Yamaguchi M, et al. Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease. *Br J Surg.* 1997;84:793–796.
78. Takeuchi S, Nakano H, Kim YK, et al. Predicting survival and post-operative complications with Tc-GSA liver scintigraphy in hepatocellular carcinoma. *Hepatogastroenterology.* 1999;46:1855–1861.
79. Mitsumori A, Nagaya I, Kimoto S, et al. Preoperative evaluation of hepatic functional reserve following hepatectomy by technetium-99m galactosyl human serum albumin liver scintigraphy and computed tomography. *Eur J Nucl Med.* 1998;25:1377–1382.

80. Kwon AH, Matsui Y, Ha-Kawa SK, et al. Functional hepatic volume measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy: comparison between hepatocyte volume and liver volume by computed tomography. *Am J Gastroenterol*. 2001;96:541–546.
81. Sato S, Mimura H, Noda T, et al. Study of quantitative evaluation of liver volume and accumulation rate of radioactive agent with single photon emission computed tomography [in Japanese]. *Radioisotopes*. 1987;36:265–269.
82. Satoh K, Yamamoto Y, Nishiyama Y, et al. ^{99m}Tc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy. *Ann Nucl Med*. 2003;17:61–67.
83. Akaki S, Okumura Y, Sasai N, et al. Hepatectomy simulation discrepancy between radionuclide receptor imaging and CT volumetry: influence of decreased unilateral portal venous flow. *Ann Nucl Med*. 2003;17:23–29.
84. Li XF, Taki J, Kinuya S, et al. Asialoglycoprotein receptor concentration in tumor-bearing livers and its fate early after their sectorial resection. *Ann Nucl Med*. 2003;17:489–493.
85. Hwang EH, Taki J, Shuke N, et al. Preoperative assessment of residual hepatic functional reserve using ^{99m}Tc-DTPA-galactosyl-human serum albumin dynamic SPECT. *J Nucl Med*. 1999;40:1644–1651.
86. Krishnamurthy S, Krishnamurthy GT. Technetium-99m-iminodiacetic acid organic anions: review of biokinetics and clinical application in hepatology. *Hepatology*. 1989;9:139–153.
87. Dinant S, de Graaf W, Verwer BJ, et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. *J Nucl Med*. 2007;48:685–692.
88. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. *N Engl J Med*. 1998;339:1217–1227.
89. Hendrikse NH, Kuipers F, Meijer C, et al. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. *Cancer Chemother Pharmacol*. 2004;54:131–138.
90. Krishnamurthy S, Krishnamurthy GT, Lieberman D, et al. Scintigraphic criteria for the diagnosis of obstructive hepatobiliary diseases with Tc-99m IDA. *Clin Nucl Med*. 1988;13:704–709.
91. Krishnamurthy GT, Lieberman DA, Brar HS. Detection, localization, and quantitation of degree of common bile duct obstruction by scintigraphy. *J Nucl Med*. 1985;26:726–735.
92. Heyman S. Hepatobiliary scintigraphy as a liver function test. *J Nucl Med*. 1994;35:436–437.
93. Ekman M, Fjalling M, Holmberg S, et al. IODIDA clearance rate: a method for measuring hepatocyte uptake function. *Transplant Proc*. 1992;24:387–388.
94. Bennink RJ, Dinant S, Erdogan D, et al. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. *J Nucl Med*. 2004;45:965–971.
95. Erdogan D, Heijnen BH, Bennink RJ, et al. Preoperative assessment of liver function: a comparison of ^{99m}Tc-Mebrofenin scintigraphy with indocyanine green clearance test. *Liver Int*. 2004;24:117–123.
96. de Graaf W, van Lienden KP, van den Esschert JW, et al. Increase in future remnant liver function after preoperative portal vein embolization. *Br J Surg*. 2011;98:825–834.
97. Lan JA, Chervu LR, Johansen KL, et al. Uptake of technetium 99m hepatobiliary imaging agents by cultured rat hepatocytes. *Gastroenterology*. 1988;95:1625–1631.
98. Vetelainen R, van VA, Gouma DJ, et al. Steatosis as a risk factor in liver surgery. *Ann Surg*. 2007;245:20–30.
99. Seifalian AM, El-Desoky A, Davidson BR. Hepatic indocyanine green uptake and excretion in a rabbit model of steatosis. *Eur Surg Res*. 2001;33:193–201.
100. Brenner DA, Waterboer T, Choi SK, et al. New aspects of hepatic fibrosis. *J Hepatol*. 2000;32:32–38.
101. Brenner DA. Molecular pathogenesis of liver fibrosis. *Trans Am Clin Climatol Assoc*. 2009;120:361–368.
102. Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much? *Am J Surg*. 2005;190:87–97.
103. Heger M, de Graaf W, Bennink RJ, et al. A clinical perspective on the criteria for liver resection and the use of liver function tests. *World J Surg*. 2010;34:868–869.